Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Empirical and definitive antimicrobial therapy received

From: Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon

Antimicrobial therapy

n (%)

Empirical antimicrobial therapy (N = 111)a

Monotherapy vs combination therapy

Monotherapy

64 (57.6)

Combination

47 (42.3)

Empirical antimicrobial therapy initiated

Meropenem

64 (57.6)

Colistin

59 (53.1)

Vancomycin

27 (24.3)

Piperacillin/tazobactam

15 (13.5)

Levofloxacin

13 (11.7)

Teicoplanin

10 (9.2)

Ceftazidime

5 (4.5)

Othersb

7 (6.3)

Definitive antimicrobial therapy (N = 87)c

Colistin

80 (92)

Meropenem

4 (4.6)

Tigecycline

3 (3.4)

  1. aAs multiple responses were recorded, numbers do not add up to 111
  2. bCefepime, amikacin, ciprofloxacin, imipenem/cilastatin, ceftriaxone, clindamycin, and ampicillin/sulbactam
  3. cTwenty-four patients out of the 111 died during the empirical therapy
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us